Copyright Reports & Markets. All rights reserved.

Global Immune Thrombocytopenic Purpura Therapeutics Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Immune Thrombocytopenic Purpura Therapeutics Market Overview

      • 1.1 Product Overview and Scope of Immune Thrombocytopenic Purpura Therapeutics
      • 1.2 Immune Thrombocytopenic Purpura Therapeutics Segment by Type
        • 1.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Eltrombopag Olamine
        • 1.2.3 Fostamatinib Disodium
        • 1.2.4 GL-2045
        • 1.2.5 Avatrombopag
        • 1.2.6 BI-655064
        • 1.2.7 Others
      • 1.3 Immune Thrombocytopenic Purpura Therapeutics Segment by Application
        • 1.3.1 Immune Thrombocytopenic Purpura Therapeutics Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Clinic
        • 1.3.4 Others
      • 1.3 Global Immune Thrombocytopenic Purpura Therapeutics Market by Region
        • 1.3.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Immune Thrombocytopenic Purpura Therapeutics Market Size
        • 1.4.1 Global Immune Thrombocytopenic Purpura Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Immune Thrombocytopenic Purpura Therapeutics Production (2014-2025)

      2 Global Immune Thrombocytopenic Purpura Therapeutics Market Competition by Manufacturers

      • 2.1 Global Immune Thrombocytopenic Purpura Therapeutics Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Immune Thrombocytopenic Purpura Therapeutics Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Immune Thrombocytopenic Purpura Therapeutics Production Sites, Area Served, Product Types
      • 2.5 Immune Thrombocytopenic Purpura Therapeutics Market Competitive Situation and Trends
        • 2.5.1 Immune Thrombocytopenic Purpura Therapeutics Market Concentration Rate
        • 2.5.2 Immune Thrombocytopenic Purpura Therapeutics Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Immune Thrombocytopenic Purpura Therapeutics Production Market Share by Regions

      • 3.1 Global Immune Thrombocytopenic Purpura Therapeutics Production Market Share by Regions
      • 3.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Immune Thrombocytopenic Purpura Therapeutics Production
        • 3.4.1 North America Immune Thrombocytopenic Purpura Therapeutics Production Growth Rate (2014-2019)
        • 3.4.2 North America Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Immune Thrombocytopenic Purpura Therapeutics Production
        • 3.5.1 Europe Immune Thrombocytopenic Purpura Therapeutics Production Growth Rate (2014-2019)
        • 3.5.2 Europe Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Immune Thrombocytopenic Purpura Therapeutics Production (2014-2019)
        • 3.6.1 China Immune Thrombocytopenic Purpura Therapeutics Production Growth Rate (2014-2019)
        • 3.6.2 China Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Immune Thrombocytopenic Purpura Therapeutics Production (2014-2019)
        • 3.7.1 Japan Immune Thrombocytopenic Purpura Therapeutics Production Growth Rate (2014-2019)
        • 3.7.2 Japan Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Immune Thrombocytopenic Purpura Therapeutics Consumption by Regions

      • 4.1 Global Immune Thrombocytopenic Purpura Therapeutics Consumption by Regions
      • 4.2 North America Immune Thrombocytopenic Purpura Therapeutics Consumption (2014-2019)
      • 4.3 Europe Immune Thrombocytopenic Purpura Therapeutics Consumption (2014-2019)
      • 4.4 China Immune Thrombocytopenic Purpura Therapeutics Consumption (2014-2019)
      • 4.5 Japan Immune Thrombocytopenic Purpura Therapeutics Consumption (2014-2019)

      5 Global Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price Trend by Type

      • 5.1 Global Immune Thrombocytopenic Purpura Therapeutics Production Market Share by Type (2014-2019)
      • 5.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2014-2019)
      • 5.3 Global Immune Thrombocytopenic Purpura Therapeutics Price by Type (2014-2019)
      • 5.4 Global Immune Thrombocytopenic Purpura Therapeutics Production Growth by Type (2014-2019)

      6 Global Immune Thrombocytopenic Purpura Therapeutics Market Analysis by Applications

      • 6.1 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Market Share by Application (2014-2019)
      • 6.2 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Immune Thrombocytopenic Purpura Therapeutics Business

      • 7.1 Amgen Inc.
        • 7.1.1 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.1.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.1.3 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Baxalta Incorporated
        • 7.2.1 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.2.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.2.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Boehringer Ingelheim GmbH
        • 7.3.1 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.3.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.3.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Bristol-Myers Squibb Company
        • 7.4.1 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.4.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.4.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Eisai
        • 7.5.1 Eisai Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.5.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.5.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Hansa Medical AB
        • 7.6.1 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.6.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Immunomedics, Inc.
        • 7.7.1 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.7.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Intas Pharmaceuticals Ltd.
        • 7.8.1 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.8.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.8.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Jiangsu Hengrui Medicine Co., Ltd.
        • 7.9.1 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.9.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.9.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Merck & Co., Inc.
        • 7.10.1 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Production Sites and Area Served
        • 7.10.2 Immune Thrombocytopenic Purpura Therapeutics Product Introduction, Application and Specification
        • 7.10.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Momenta Pharmaceuticals, Inc.
      • 7.12 Novartis AG
      • 7.13 Pfizer Inc.

      8 Immune Thrombocytopenic Purpura Therapeutics Manufacturing Cost Analysis

      • 8.1 Immune Thrombocytopenic Purpura Therapeutics Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Immune Thrombocytopenic Purpura Therapeutics
      • 8.4 Immune Thrombocytopenic Purpura Therapeutics Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Immune Thrombocytopenic Purpura Therapeutics Distributors List
      • 9.3 Immune Thrombocytopenic Purpura Therapeutics Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Immune Thrombocytopenic Purpura Therapeutics Market Forecast

      • 11.1 Global Immune Thrombocytopenic Purpura Therapeutics Production, Revenue Forecast
        • 11.1.1 Global Immune Thrombocytopenic Purpura Therapeutics Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Immune Thrombocytopenic Purpura Therapeutics Price and Trend Forecast (2019-2025)
      • 11.2 Global Immune Thrombocytopenic Purpura Therapeutics Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Immune Thrombocytopenic Purpura Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Immune Thrombocytopenic Purpura Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Immune Thrombocytopenic Purpura Therapeutics Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Immune Thrombocytopenic Purpura Therapeutics Production, Revenue Forecast (2019-2025)
      • 11.3 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2019-2025)
        • 11.3.2 Europe Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2019-2025)
        • 11.3.3 China Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2019-2025)
        • 11.3.4 Japan Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast (2019-2025)
      • 11.4 Global Immune Thrombocytopenic Purpura Therapeutics Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Immune Thrombocytopenic Purpura Therapeutics Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Immune Thrombocytopenic Purpura Therapeutics market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Immune Thrombocytopenic Purpura Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Immune Thrombocytopenic Purpura Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Amgen Inc.
        Baxalta Incorporated
        Boehringer Ingelheim GmbH
        Bristol-Myers Squibb Company
        Eisai
        Hansa Medical AB
        Immunomedics, Inc.
        Intas Pharmaceuticals Ltd.
        Jiangsu Hengrui Medicine Co., Ltd.
        Merck & Co., Inc.
        Momenta Pharmaceuticals, Inc.
        Novartis AG
        Pfizer Inc.

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Eltrombopag Olamine
        Fostamatinib Disodium
        GL-2045
        Avatrombopag
        BI-655064
        Others

        Segment by Application
        Hospital
        Clinic
        Others

        Buy now